Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / IL8

IL8

Basics

Aliases:
This biomarker is also known as:
  • Neutrophil-activating protein 1,
  • 3-10C,
  • GCP-1,
  • small inducible cytokine subfamily B, member 8,
  • GCP1,
  • neutrophil-activating peptide 1,
  • Granulocyte chemotactic protein,
  • LYNAP,
  • chemokine (C-X-C motif) ligand 8,
  • Protein 3-10C,
  • IL-8,
  • interleukin-8,
  • MDNCF,
  • CXCL8,
  • T-cell chemotactic factor,
  • C-X-C motif chemokine 8,
  • beta-thromboglobulin-like protein,
  • MONAP,
  • lymphocyte-derived neutrophil-activating factor,
  • AMCF-I,
  • LUCT,
  • NAP-1,
  • interleukin 8,
  • Monocyte-derived neutrophil-activating peptide,
  • emoctakin,
  • T cell chemotactic factor,
  • NAP1,
  • OTTHUMP00000199825,
  • LECT,
  • NAF,
  • Emoctakin,

View in BioMuta

Description…

Interleukin 8 (IL8) is a member of the CXC chemokine family. This chemokine functions as a chemoattractant, or chemotactic factor, that attracts neutrophils, basophils, and T-cells, but not monocytes. IL8 is one of the major mediators of the inflammatory response, and is involved in neutrophil activation. It is released from several types of cells in response to an inflammatory stimulus. IL8 also functions as an angiogenic factor. The IL8 gene maps to chromosome 4q, and is found in a chemokine gene cluster along with ten other members of the CXC chemokine gene family. There are several N-terminal processed forms that are produced by proteolytic cleavage after secretion from at least peripheral blood monocytes, leukcocytes and endothelial cells. Among the forms are: IL-8(1-77), IL-8(5-77), IL-8(6-77), IL-8(7-77), IL-8(8-77), IL-8(9-77). IL-8(1-77) is generally referred to as interleukin 8. IL-8(6-77) is the most promiment form.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: IL8

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Two
QA State: Under Review

Overview

Performance Comment

Levels of IL8 in exhaled breath condensate indicated acute inflammation but were not indicative of lung cancer.

Ovary

Attributes

Phase: Two
QA State: Under Review

Overview

IL8 alone was not shown to be a strong predictor of ovarian cancer.

Performance Comment

Despite many promising new markers for ovarian cancer, CA125 remains the single best biomarker in the phase II and phase III specimens tested in this study.

Prostate

Attributes

Phase: One
QA State: Under Review

Overview

Performance Comment

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.